
==== Front
Curr Dev Nutr
Curr Dev Nutr
Current Developments in Nutrition
2475-2991
American Society for Nutrition

S2475-2991(23)26639-1
10.1016/j.cdnut.2023.102055
102055
Original Research
Effects of Citrus Flavanone Hesperidin Extracts or Purified Hesperidin Consumption on Risk Factors for Cardiovascular Disease: Evidence From an Updated Meta-analysis of Randomized Controlled Trials
Huang Haohai haohaihuang@hotmail.com
12∗
Liao Dan 3
He Bin 1
Zhou Guanghui 4
Cui Yejia 5
1 Clinical Translational Medical Center, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, Guangdong, China
2 Department of Clinical Pharmacy, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, Guangdong, China
3 Department of Gynaecology, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, Guangdong, China
4 Department of Rehabilitation Medicine, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, Guangdong, China
5 Department of Clinical Laboratory, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, Guangdong, China
∗ Corresponding author. Clinical Translational Medicine Center, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, Guangdong, China. haohaihuang@hotmail.com
09 12 2023
9 2024
09 12 2023
8 9 1020556 10 2023
21 11 2023
4 12 2023
© 2023 Published by Elsevier Inc. on behalf of American Society for Nutrition.
2023

https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Background

Cardiovascular disease (CVD) is a serious public health problem worldwide. The role of citrus flavanone hesperidin consumption on cardiovascular disease risk factors (CVDRFs) has been examined in many clinical trials, but conflicting results have been found.

Objectives

This study aimed to systematically evaluate the effects of hesperidin extracts or purified hesperidin on CVDRFs in humans with an updated meta-analysis of randomized controlled trials.

Methods

According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, we systematically screened and searched electronic databases from their establishment to March 2023. Reference lists and previous reviews were also searched. Intervention trials assessing hesperidin consumption on CVD outcomes were included for pooling. To assess the quality of the included articles, the tool of Cochrane risk-of-bias tool was applied. We synthesized the effect sizes with 95% CIs and weighted mean difference (WMD). The I2 index was used to evaluate the between-study heterogeneity. To explore the heterogeneity source, we used meta-regression and subgroup analysis. Publication bias and sensitivity analysis were also performed. We used the Grading of Recommendations Assessment, Development, and Evaluation approach to evaluate the evidence quality.

Results

We included 12 trials with 589 participants. We found evident effects of hesperidin on low-density lipoprotein cholesterol (WMD: −0.22 mmol/L; 95% CI: −0.33, −0.11 mmol/L), total cholesterol (WMD: −0.20 mmol/L; 95% CI: −0.31, −0.08 mmol/L), fasting blood glucose (WMD: −0.15 mg/dL; 95% CI: −0.29, −0.02 mg/dL), quantitative insulin-sensitivity check index (WMD 0.06, 95% CI 0.01 to 0.10), intercellular adhesion molecule 1 (WMD: −13.60 ng/mL; 95% CI: −23.72, −3.48 ng/mL), vascular cell adhesion molecule 1 (WMD: −15.60 ng/mL; 95% CI: −30.13, −1.06 ng/mL), and C-reactive protein (WMD: −0.56 mg/L; 95% CI: −1.11, −0.01 mg/L), whereas no effects were found for other CVDRFs.

Conclusions

Our current findings demonstrate that hesperidin might be advantageous in improving numerous CVDRFs in humans, such as blood lipid concentrations, blood glucose control, and management of inflammatory indicators.

Keywords

blood pressure
CVD
lipid
hesperidin
glucose
meta-analysis
inflammation
Abbreviations

BMI body mass index

BW body weight

CRP C-reactive protein

CVD cardiovascular disease

CVDRF cardiovascular diseases risk factor

DBP diastolic blood pressure

FBG fasting blood glucose

GRADE Grading of Recommendations Assessment, Development, and Evaluation

HC hip circumference

HDL high-density lipoprotein

HOMA-IR homeostatic model assessment of insulin resistance

ICAM intercellular adhesion molecule

LDL low-density lipoprotein

QUICKI quantitative insulin-sensitivity check index

SBP systolic blood pressure

TC total cholesterol

TG triglyceride

VCAM vascular cell adhesion molecule

WC waist circumference

WMD weighted mean difference
==== Body
pmcIntroduction

Cardiovascular disease (CVD) is a serious public health problem and is significantly connected to most disabilities, morbidities, and mortalities worldwide [1,2]. With the global aging of populations, the prevalence of CVD is increasing rapidly. Several modifiable cardiovascular disease risk factors (CVDRFs), such as inappropriate diet, inflammation, type 2 diabetes, obesity, hypertension, insulin resistance, and dyslipidemia, are related to CVD development and associated complications [[3], [4], [5]]. Previous studies have shown that controlling these CVDRFs can decrease or prevent the CVD development [6,7]. Owing to its health and financial burden on society, primary and secondary CVD prevention and delaying the occurrence and progression of CVD-related problems are crucial for public health. According to the literature from randomized controlled trials (RCTs) and epidemiology, natural dietary products and nutraceutical therapies significantly affect CVD prevention and management for many reasons, such as poor adherence to medications, drug contraindications, various side effects, or individual preference for natural or alternative therapies [8,9].

In European adults, the mean flavonoid intake is 428 mg/d [10]. Flavanones, such as hesperidin, is a bioactive plant compound that is mainly found in citrus fruits, such as lemons, clementine, grapefruit, and mandarins and their juices [11]. Hesperidin, which accounts for ∼90% of the flavanone glycosides in orange juice, is mainly concentrated in the solid parts and membranes that separate the pulp segments of citrus fruits [12]. In single-strength juice, hesperidin content ranges from 555 to 761 mg/L, whereas in concentrated juice, it ranges from 470 to 614 mg/L [13]. Supplementation with hesperidin has various benefits, such as anti-inflammatory, anticancer, and antioxidant characteristics [[14], [15], [16]]. In addition, many animal and human studies have explored hesperidin’s cardiovascular preventive benefits [[17], [18], [19]]. RCTs have also investigated the effectiveness of hesperidin consumption on various CVDRFs [[20], [21], [22], [23]]. However, very small sample sizes, different supplementation dosages, and diverse underlying health states hampered the outcomes and made them inconsistent. Two previous systematic review and meta-analyses summarized the evidence on the effects of hesperidin on CVDRFs [24,25]. The study conducted by Mohammadi et al. [24], including 10 RCTs showed that the hesperidin supplementation might not improve lipid profile and blood pressure. However, the effects of hesperidin consumption on markers related to body composition, glycemic indices, and inflammation were not evaluated in this study. Another meta-analysis conducted by Pla-Pagà et al. [25] revealed that hesperidin consumption reduces glucose concentrations and various lipid profile parameters in animal studies. However, a definitive conclusion cannot be drawn in the human clinical trials. Of note, 7 publications included in the previous meta-analysis analyzed consumption of orange juice [[26], [27], [28], [29], [30], [31], [32]], not the purified hesperidin or standardized hesperidin–enriched extracts. The compositions of the orange juice contained hesperidin, naringin, vitamin C, folate, total sugar, didymin, and citric acid. The beneficial effect of hesperidin supplementation on CVDRFs could be attributed to other nutrients consumption. Thus, it may be improper to include these studies for pooling. Overall, the previous meta-analyses might threaten the authenticity of their findings. To provide the latest and most convincing evidence, we performed a systematic review and meta-analysis of human RCTs that evaluated the consumption of citrus flavanone hesperidin extract or purified hesperidin on cardiometabolic health outcomes.

Methods

We conducted the design, implementation, and reporting according to the PRISMA 2020 guidelines [33].

Strategy for literature search

In this study, the keyword-based search was performed by 2 authors (HH and DL) in Cochrane Central Register of Controlled Trials, MEDLINE/PubMed, Google Scholar, Scopus, EMBASE, and Web of Science, from their establishment to March 2023, without using language restrictions, to find all eligible RCTs regarding the clinical effectiveness of hesperidin on CVDRFs in adults. The complete search strategy, including Medical Subjects Headings and free-text terms, are provided in Supplemental Table 1. Related reviews and references cited by the included articles were also screened to find more relevant articles.

Study inclusion and exclusion criteria

After comprehensive reading of the titles, abstracts, and full texts, the following inclusion criteria were used to select eligible studies:• Participants: adults (age >18 y);

• Intervention: subjects needed to have specifically ingested purified hesperidin or standardized hesperidin–enriched extracts; the hesperidin and other combined intervention trials were selected when these combined interventions were used as the control group, with an intervention duration of ≥2 wk;

• Comparators: no hesperidin consumption or placebo capsule (cellulose and starch) interventions or consumed substitutions containing no hesperidin;

• Outcomes: relevant cardiovascular health primary outcomes included markers related to lipid profile, blood pressure, body composition, glycemic indices, and inflammation;

• Study design: original RCTs with a parallel or crossover design.

Excluded from the analysis were duplicate data, nonrandomized study designs, animal studies, studies using an active comparator (such as grape or apple juice) in the control group, studies lacking a control group, and reviews. Furthermore, studies with ambiguous information and those lacking response from the corresponding authors despite attempts to contact them were also excluded.

Data extraction and quality assessment

Data were retrieved by 2 researchers (GZ and BH). If the same patients were mentioned in multiple publications but with variations in reported outcomes, we included all publications. However, the sample size from these publications was only considered once during calculations. Nonagreements were resolved by a third researcher (DL). We extracted the following characteristics from each included study:• Publication data: first author’s name, year of publication, and country in which the trial was performed;

• Participant characteristics: mean age, health condition, and sex;

• Study characteristics: enrolled and completed patient number, hesperidin dosage and formulation, control treatment type, intervention duration, and details of the study design;

• Study outcomes: means and SDs of primary outcomes at baseline, posttreatment, or changes between baseline and posttreatment. Serious adverse events were also extracted. Based on the Cochrane Handbook for Systematic Reviews of Interventions [34], SDs were estimated using the SE or 95% CIs when they were not directly available.

We applied the Cochrane risk-of-bias tool for RCTs. Criteria, such as incomplete outcome data, blinding of outcome assessment, selective reporting, blinding of participants and personnel, random sequence generation, and allocation concealment, were applied to evaluate the characteristics’ quality. According to the suggestions from the Cochrane Handbook, a qualitative degree (no, yes, or unclear) was assigned for each item, and judgment of each included study was labeled with unclear, high, or low risk of bias.

Synthesis and analysis of data

We used the DerSimonian and Laird random-effects model to calculate the 95% CIs and the weighted mean difference (WMD) for continuous outcomes. The I2 index and the Q test evaluated the heterogeneity between trials. I2 scores of ≥50% indicated moderate to high heterogeneity [35]. A conventional analysis of sensitivity was conducted by removing 1 study at a time to examine whether the overall results relied on individual studies. Then, we performed a priori analysis of subgroup to find probable causes of heterogeneity when there were sufficient numbers of studies. The publication bias probability was examined using the asymmetry of Egger weighted regression statistics, Begg rank correlation, and funnel plot [36,37]. We used a random-effects meta-regression analysis based on the restricted maximum likelihood to determine whether the duration and amount of hesperidin supplementation were related to the heterogeneity source [38]. We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) technique to evaluate the evidence quality for each metabolic and cardiovascular biomarker. The evidence quality was classified to very low, low, moderate, and high [39]. RevMan (version 12.0) and STATA (version 5.0) were applied for all statistical analyses. Two-sided comparisons were applied in all analyses unless stated otherwise. A significant difference was set as a P value of <0.05.

Results

Main search

Based on the search strategy, 423 records were identified in Cochrane Central Register of Controlled Trials (n = 75), PubMed (n = 113), Google Scholar (n = 54), Scopus (n = 51), EMBASE (n = 86), and Web of Science (n = 44). Eight additional studies were included using reference lists from the included reviews. After duplication analysis (n = 115), 276 publications were excluded based on the review of titles and abstracts. We also removed reviews (n = 3) or meta-analyses and systematic reviews (n = 4), studies that did not provide adequate data for the outcomes (n = 6), those that did not report the primary outcomes, studies with treatment periods of <2 wk (n = 1), studies that were not an RCT (n = 1), or studies that used mixture of hesperidin and other nutrients (n = 15). Finally, 12 publications were included in this meta-analysis to evaluate the effects of hesperidin on cardiovascular health [[20], [21], [22], [23],[40], [41], [42], [43], [44], [45], [46], [47]]. Details of the flow diagram of study selection are shown in Figure 1.FIGURE 1 Selection of studies for inclusion. RCT, randomized controlled trial.

FIGURE 1

Subjects and study characteristics

Study characteristics and the main participant information are presented in Table 1. The number of participants in each trial ranged from 24 to 124. We included 608 participants, and 96.58% (589) completed the studies.TABLE 1 Characteristics of study populations, type of interventions, and study designs in the included trials

TABLE 1Study	Year	Study design	Country	Sample size (enrolment/completed)	Sex (M/F)	Study participants	Mean age1	BMI (kg/m2)1	Intervention	Dose (mg/d)	Duration (wk)	Outcomes1	
Treatment group	Control group	
Salden et al. [20]	2016	R, PC, DB, P	Netherlands	68/68	29/39	Healthy overweight individuals	53.00	29.00	Hesperidin 2S	Placebo (cellulose)	450	6	VCAM-1, ICAM-1, E-selectin, SBP, DBP, TC, LDL cholesterol, HDL cholesterol, TG, FBS, insulin, QUICKI	
Rizza et al. [45]	2011	R, PC, DB, C	Italy	24/24	15/9	Patients with metabolic syndrome	52.00	34.70	Hesperidin	Placebo (cellulose)	500	3	SBP, DBP, CRP, VCAM, E-selectin, BMI, WC, FBG, insulin, HOMA-IR, TC, LDL cholesterol, HDL cholesterol, TG, QUICKI	
Morand et al. [44]	2011	R, PC, C	France	24/24	24/0	Healthy subjects with no evidence of chronic disease	56.00	27.4	Control drink plus hesperidin	Control drink plus placebo (starch)	292	4	SBP, DBP, FBG, insulin, TC, LDL cholesterol, HDL cholesterol, TG, CRP, ICAM-1, VCAM-1	
Demonty et al. [41]	2010	R, PC, DB, P	Netherlands	124/124	65/59	Moderately hypercholesterolemic individuals	60.55	25.10	Hesperidin	Placebo (microcrystalline cellulose)	800	4	BW, BMI, TC, LDL cholesterol, HDL cholesterol, TG	
Homayouni et al. [21]	2018	R, PC, DB, P	Iran	64/60	NA	Type 2 diabetes	52.85	27.75	Hesperidin	Placebo (starch)	500	6	BW, BMI, SBP, DBP, CRP	
Homayouni et al. [43]	2017	R, PC, DB, P	Iran	64/60	NA	Type 2 diabetes	52.83	27.73	Hesperidin	Placebo (starch)	500	6	BW, BMI, FBG, HOMA-IR	
Ohara et al. [22]	2016	R, PC, DB, P	Japan	30/29	14/15	Healthy, moderately obese subjects	49.20	26.15	Glucosyl-hesperidin	Placebo	500	12	BW, BMI, WC, HC, TC, LDL cholesterol, HDL cholesterol, TG	
Cheraghpour et al. [40]	2019	R, PC, DB, P	Iran	50/49	22/27	Patients with nonalcoholic fatty liver disease	47.30	32.43	Hesperidin	Placebo	1000	12	FBS, insulin, HOMA-IR, TC, LDL cholesterol, HDL cholesterol, TG, CRP	
Haidari et al. [42]	2015	R, PC, DB, P	Iran	75/75	NA	Patients with myocardial infarction	55.49	26.39	Hesperidin	Placebo (starch)	600	4	BW, BMI, WC, HC, SBP, DBP, CRP, E-selectin, TC, LDL cholesterol, HDL cholesterol, TG	
Yari et al. [23]	2020	R, PC, C	Iran	49/44	23/21	Patients with metabolic syndrome	46.12	31.53	Hesperidin	No supplement	1000	12	BW, BMI, WC, TG, HDL cholesterol, FBS, insulin, HOMA-IR, SBP, DBP, QUICKI	
Yari et al. [46]	2021	R, PC, DB, P	Iran	50/49	25/24	Patients with metabolic syndrome	45.19	31.31	Hesperidin	Placebo (starch)	1000	12		
Yari et al. [47]	2021	R, PC	Iran	50/43	21/22	Patients with nonalcoholic fatty liver disease	45.97	32.06	Lifestyle modification program with hesperidin supplementation	Lifestyle modification program	1000	12	BMI, WC, FBS, insulin, HOMA-IR, TC, LDL cholesterol, HDL cholesterol, TG, CRP, QUICKI	
BMI, body mass index; BW, body weight; C, crossover; CRP, C-reactive protein; DB, double-blind; DBP, diastolic blood pressure; F, female; FBG, fasting blood glucose; HC, hip circumference; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; ICAM, intercellular adhesion molecule; LDL, low-density lipoprotein; M, male; NA, not available; P, parallel; PC, placebo-controlled; R, randomized; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; VCAM, vascular cell adhesion molecule; WC, waist circumference.

1 Values for age and BMI are expressed as mean unless otherwise stated.

Publication details.

The publication date ranged from 2010 to 2020. Researchers from 5 countries performed these studies: Netherlands (n = 2) [20,41], Italy (n = 1) [45], France (n = 1) [44], Japan (n = 1) [22], and Iran (n = 7) [21,23,40,42,43,46,47].

Subject characteristics.

In each trial, the number of participants ranged from 24 to 124, and 649 individuals were finally included for data pooling. One study included only male subjects, 8 included both sexes, and 3 did not specify gender composition. The average age ranged from 45.19 to 60.55 y, and the BMI (kg/m2) values ranged between 25.10 and 34.70. Healthy subjects were enrolled in only 3 studies [20,22,44]. Other trials were performed among participants with various diseases, such as type 2 diabetes (n = 2) [21,43], nonalcoholic fatty liver disease (n = 2) [40,46], metabolic syndrome (n = 3) [23,45,47], hypercholesterolemia (n = 1) [41], and myocardial infarction (n = 1) [42].

Study characteristics.

The doses of hesperidin administered ranged from 292 to 1000 mg/d. Ten trials used hesperidin [21,23,[40], [41], [42], [43], [44], [45], [46], [47]], 1 used hesperidin 2S [20], and 1 used G-hesperidin [22]. Placebo control interventions included cellulose, starch, or microcrystalline cellulose. The duration of the intervention ranged from 3 to 12 wk. Four trials were designed as parallel-group studies [[44], [45], [46], [47]], and 8 used a parallel design [[20], [21], [22], [23],[40], [41], [42], [43]].

Outcome measurement.

In these enrolled studies, the CVDRFs included E-selectin, intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, C-reactive protein (CRP), waist circumference (WC), body weight (BW), hip circumference (HC), quantitative insulin-sensitivity check index (QUICKI), BMI, HOMA-IR, insulin, fasting blood glucose (FBG), diastolic blood pressure (DBP), systolic blood pressure (SBP), triglycerides (TGs), HDL cholesterol, LDL cholesterol, and total cholesterol (TC). Twelve trials investigated the effects of hesperidin on lipid profile; 8 on FBG and BMI; 7 on BP, insulin, and BW; 6 on WC and CRP; 5 on HOMA-IR and QUICKI; 3 on VCAM-1 and E-selectin; and 2 on HC and ICAM-1.

Trial quality evaluation.

A summary of the Cochrane Collaboration tool’s risk-of-bias assessment is presented in Figure 2. A high risk of bias was found in 3 studies [23,44,47], an unknown risk was observed in 7 studies [[20], [21], [22],[41], [42], [43],45], and a low risk was discovered in 2 studies [40,46]. Thus, 2 studies were rated as high quality, whereas others were rated as fair and poor.FIGURE 2 Quality assessment of the included studies. Question mark indicates an unclear or unknown risk of bias; negative sign indicates a high risk of bias; positive sign indicates a low risk of bias.

FIGURE 2

Quantitative data synthesis from the overall meta-analysis and subgroup analysis

We included 12 studies with 589 participants on the effects of hesperidin on CVDRFs. We performed analysis of prespecified subgroup to explore the overall effects of hesperidin in CVDRFs effects, including mean age (>50 compared with <50 y), study design (crossover compared with parallel design), baseline BMI (<30 compared with ≥30), hesperidin dose (<500 compared with ≥500 mg/d), and the intervention duration (<6 compared with ≥6 wk) (Supplemental Table 2).

Effects of hesperidin supplementation on lipid profile

By using a random-effects model, the pooled results suggested that hesperidin supplementation significantly reduced the concentrations of TC (WMD: −0.20 mmol/L; 95% CI: −0.31, −0.08 mmol/L; P = 0.0006; I2 = 0%) and LDL cholesterol (WMD: −0.22 mmol/L; 95% CI: −0.33, −0.11 mmol/L; P = 0.00001; I2 = 0%). However, the overall analysis showed that hesperidin did not affect HDL cholesterol (WMD: 0.03 mmol/L; 95% CI: −0.01, 0.07 mmol/L; P = 0.17; I2 = 0%) and TG (WMD: −0.18 mmol/L; 95% CI: −0.38, 0.01 mmol/L; P = 0.07; I2 = 79.7%) concentrations. A forest plot for hesperidin effects on lipid profile is shown in Figure 3. Subgroup analyses were also performed to clarify the hesperidin effects on plasma lipid levels in some prespecified subgroups. We found that hesperidin significantly reduced LDL cholesterol and TC (P < 0.05) concentrations in the following subgroups: hesperidin ≥500 mg/d, duration ≥6 wk, parallel design, mean BMI ≥30, and mean age of <50 y. Moreover, HC significantly decreased TG in subjects with BMI ≥30 and <50 y and trials with crossover design and duration of ≥6 wk.FIGURE 3 Forest plot illustrating the weighted mean difference of hesperidin on blood lipids with a random-effects model: (A) TC; (B) LDL cholesterol; (C) HDL cholesterol; (D) TG. HDL cholesterol, high-density lipoprotein cholesterol; LDL cholesterol, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride.

FIGURE 3

Effects of hesperidin supplementation on blood pressure

Hesperidin intervention did not affect SBP (WMD: −1.98 mm Hg; 95% CI: −4.49, 0.53 mm Hg; P = 0.12) and DBP (WMD: −0.28 mm Hg; 95% CI: −2.14, 1.58 mm Hg; P = 0.77) (Figure 4). No significant heterogeneity was detected in the RCTs for SBP and DBP (I2 = 0%). Similarly, we did not find significant effects of hesperidin on SBP and DBP in the subgroup analysis based on study design, mean age, intervention duration, mean BMI, and hesperidin dose.FIGURE 4 Forest plot illustrating the weighted mean difference of hesperidin on blood pressure with a random-effects model: (A) SBP; (B) DBP. DBP, diastolic blood pressure; SBP, systolic blood pressure.

FIGURE 4

Effects of hesperidin supplementation on glycemic indices

Hesperidin had an inhibitory effect on FBG (WMD: −0.15 mg/dL; 95% CI: −0.29, −0.02 mg/dL; P = 0.02; I2 = 0%) and QUICKI (WMD: 0.06; 95% CI: 0.01, 0.10; P = 0.02; I2 = 99%). However, insulin (WMD: 0.57 μU/mL; 95% CI: −0.60, 1.74 μU/mL; P = 0.41; I2 = 0%) and HOMA-IR (WMD: 0.03; 95% CI: −0.34, 0.41; P = 0.86; I2 = 0%) did not differ compared with the control group (Figure 5). We also found a significant reduction in FBG for subjects with BMI of ≥30, subjects <50 y, dosages ≥500 mg/d, duration ≥6 wk, and crossover design. Meanwhile, we detected a significant change in QUICKI in subjects with BMI of <30 and dosages <500 mg/d.FIGURE 5 Forest plot illustrating the weighted mean difference of hesperidin on glycemic control with a random-effects model: (A) FBG; (B) insulin; (C) HOMA-IR. FBG, fasting blood glucose; HOMA-IR, homeostatic model assessment of insulin resistance.

FIGURE 5

Effects of hesperidin supplementation on body composition and inflammatory markers

In comparison with the control group, hesperidin intake did not affect the BW (WMD: 0.08 kg; 95% CI: −0.18, −0.33 kg; P = 0.55; I2 = 0%), BMI (WMD: −0.05 kg/m2; 95% CI: −0.58, 0.47 kg/m2; P = 0.84; I2 = 0%), WC (WMD: −1.45 cm; 95% CI: −3.23, 0.33 cm; P = 0.11; I2 = 28%), and HC (WMD: −0.73 cm; 95% CI: −1.69, 0.22 cm; P = 0.13; I2 = 0%) (Table 2). Meanwhile, the subgroup analysis demonstrated that hesperidin decreased WC (P < 0.05) in subjects with BMI of ≥30 and trials with a crossover design.TABLE 2 Effect of hesperidin consumption on body composition and inflammation markers in human subjects

TABLE 2Outcomes	No. of trials	No. of patients	WMD (95% CI)	P	I2 (%)	P-heterogeneity	
BW	7	382	0.08 (−0.18, 0.33)	0.55	0	1.00	
BMI	8	424	−0.05 (−0.58, 0.47)	0.84	0	0.95	
WC	6	289	−1.45 (−3.23, 0.33)	0.11	28	0.22	
HC	2	105	−0.73 (−1.69, 0.22)	0.13	0	0.79	
CRP	6	324	−0.56 (−1.11, −0.01)	0.041	56	0.05	
VCAM-1	3	144	−15.60 (−30.13, −1.06)	0.041	87	0.006	
ICAM-1	2	96	−13.60 (−23.72, −3.48)	0.0081	62	0.10	
E-selectin	3	171	−2.25 (−6.14, 1.64)	0.26	59	0.09	
BMI, body mass index; BW, body weight; CRP, C-reactive protein; HC, hip circumference; ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule; WC, waist circumference.

1 Indicates a significant result.

We also evaluated the effects of hesperidin ingestion on inflammation markers, such as VCAM-1, ICAM-1, E-selectin, and CRP. Hesperidin significantly reduced CRP (WMD: −0.56 mg/L; 95% CI: −1.11, −0.01 mg/L; P = 0.048; I2 = 56%), VCAM-1 (WMD: −15.60 ng/mL; 95% CI: −30.13, −1.06 ng/mL; P = 0.04; I2 = 87%), and ICAM-1 (WMD: −13.60 ng/mL; 95% CI: −23.72, −3.48 ng/mL; P = 0.008; I2 = 62%). However, hesperidin did not affect E-selectin (WMD: −2.25 ng/mL; 95% CI: −6.14, 1.64 ng/mL; P = 0.826; I2 = 59%) (Table 1). In addition, we found a significant reduction in CRP for subjects with BMI of ≥30, subjects aged <50 y, dosages ≥500 mg/d, duration ≥6 wks, and crossover design.

Clinical safety evaluation

No serious adverse effects were found in most trials after hesperidin consumption, suggesting a good tolerance to hesperidin. Only 1 RCT recorded adverse effects during the study period. Ohara et al. [22] reported that 6 participants receiving G-hesperidin (500 mg/d) presented symptoms of a common cold (n = 3), pain (n = 2), and conjunctivitis (n = 1).

Sensitivity analyses

We also conducted sensitivity analyses to verify the robustness of the results. The pooled results or overall effect size for CVDRFs remained solid and were not sensitive to any individual study. Moreover, after using the fixed-effects model, the analysis of sensitivity revealed that the combined effects of hesperidin on CVDRFs did not significantly change (Supplemental Table 3).

Dose–response relation between doses and duration of hesperidin intake and outcomes

Because hesperidin was supplied at various doses and durations in the included trials, the correlation of changes in CVDRFs with hesperidin dosage (milligrams per day) and duration (weeks) were evaluated (Supplemental Table 4). We did not detect a between the duration of supplementation and the impact of hesperidin on CRP, WC, BMI, BW, insulin, FBG, DBP, SBP, HDL cholesterol, LDL cholesterol, and TC (P > 0.05). Meanwhile, the hesperidin amount consumed per day was not related to changes in CRP, WC, BMI, BW, Insulin, FBG, DBP, SBP, HDL cholesterol, TC, and LDL cholesterol (P > 0.05). However, the meta-regression analysis showed that the efficacy of hesperidin in lowering TG concentrations significantly increased with increasing doses (coefficient: −0.0007; 95% CI: −0.0014, −0.0008; P = 0.031) and duration (coefficient: −0.0563; 95% CI: −0.0841, −0.0286; P = 0.002). We did not perform a dose–response relation test for HOMA-IR, QUICKI, HC, ICAM-1, VCAM-1, and E-selectin owing to insufficient data (n ≤ 5).

GRADE evidence profile assessment

The GRADE profiles for the clinical evidence of hesperidin consumption on blood lipids, blood pressure, glycemic indices, inflammatory markers, and BW management are presented in Supplemental Table 5. In the GRADE Working Group evidence level rates, we found very low quality for QUICKI; low quality for HC, CRP, E-selectin, VCAM-1, and ICAM-1; moderate quality for TG, insulin, HOMA-IR, and WC; and high quality for TC, LDL cholesterol, HDL cholesterol, SBP, DBP, FBG, BW, and BMI.

Publication bias assessment

Based on the funnel plots, we did not discover any significant publication bias (Figure 6). Furthermore, consistent results were obtained using the tests of Begg rank correlation and Egger linear regression (P > 0.05) (Supplemental Table 6). Because the number of the included trials was small (n ≤ 5), we did not evaluate the publication bias or HOMA-IR or QUICKI, HC, E-selectin, VCAM-1, and ICAM-1.FIGURE 6 Funnel plot demonstrating publication bias in the studies reporting the impact of hesperidin on CVDRFs: (A) TC; (B) LDL cholesterol; (C) HDL cholesterol; (D) TG; (E) SBP; (F) DBP; (G) FBG; (H) insulin; (I) BW; (J) BMI; (K) WC; (L) CRP. BW, body weight; CRP, C-reactive protein; DBP, diastolic blood pressure; FBG, fasting blood glucose; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; WC, waist circumference.

FIGURE 6

Discussion

Hesperidin is a commonly found flavanone and is a potential agent for the modulation and therapy of CVD and its associated complications. Many studies have shown that hesperidin and its derivative chemicals help improve CVDRFs, such as hypertension, adiposity, and glucose and lipid metabolism. Meanwhile, inconsistent conclusions were obtained from different clinical trials. In this review, we summarized the available scientific data on the beneficial effects of hesperidin extracts or purified hesperidin ingestion on the biomarkers associated with CVD risk acquired in RCTs. For statistical pooling, we included 12 trials with 589 individuals. We found that hesperidin positively affects TC, LDL cholesterol, FBG, QUICKI, CRP, VCAM-1, and ICAM-1. However, compared with the control group, the HDL cholesterol, TG, SBP, DBP, insulin, HOMA-IR, BW, BMI, WC, HC, and E-selectin were not changed after hesperidin supplementation treatment. According to our subgroup analysis, hesperidin intake dramatically suppressed DBP, SBP, TG, and TC levels in the following subgroups: hesperidin ≥ 500 mg/d, mean age <50 y, mean BMI ≥30, duration ≥6 weeks, and parallel design. In addition, hesperidin supplementation significantly changed TG, FBG, and WC levels in participants with BMI ≥ 30 and trials with a crossover design (P < 0.05). Citrus fruits and juices are widely consumed globally and serve as easily accessible dietary sources of hesperidin. Hesperidin is one of the most promising bioflavonoids, which can be efficiently extracted from the waste residues generated during citrus fruit processing, making it economically advantageous [48]. Hesperidin supplements, either alone or in combination with other citrus bioflavonoids, are commercially available. Hence, consuming hesperidin might be a beneficial dietary strategy for reducing hyperglycemia and hypercholesterolemia, especially in particular patient subgroups.

Lipoprotein and lipid metabolism dysregulation is significantly connected to the pathogenesis of many human disorders, such as CVDs [49]. Observational epidemiologic evidence indicates that individuals with hyperlipidemia have a 3-fold higher risk of heart attack than the general population with normal lipid concentrations, and a 1% reduction in serum cholesterol is strongly correlated with a 3% decrease in CVD risk [4,50]. The advantages of lowering LDL cholesterol, with a 1% reduction being linked to a corresponding 1% decrease in CVD events [51]. The main goal of drug therapy is to gradually attain lower LDL cholesterol levels to address cholesterol issues and prevent CVD. In this study, we found that hesperidin modifies dyslipidemia and subsequently affects atherosclerosis, exhibiting lipid-lowering effects. Hesperidin might also decrease cholesterol, although the exact processes underlying these effects are not entirely understood. Hesperidin can favor lipid metabolism by inhibiting the activities of phosphatidate phosphohydrolase, glucose-6-phosphate dehydrogenase, and hepatic fatty acid synthase [52]. Moreover, hesperidin treatment decreases plasma and hepatic cholesterol concentrations by downregulating the activities of HMG-CoA reductase and ACAT [53]. Hesperidin administration also decreases lipid synthesis while increasing lipolysis in adipocytes prepared from human mesenchymal stem cells [54].

Moreover, we showed that participants treated with hesperidin had statistically significantly lower FBG, which seems to contradict the previous study [55]. FBG concentration are considered a key variable in the diagnosis of diabetes and are also adopted by the Food and Drug Administration to evaluate the efficacy of dietary supplements and drugs. Hesperidin exerts its glucose-lowering properties by regulating the enzymes in glucose metabolism, enhancing glucokinase activity, and impairing gluconeogenic glucose-6-phosphatase [56,57]. Furthermore, hesperidin has antidiabetic properties by suppressing the formation of advanced glycation end products and oxidative stress and enhancing glucose uptake [58].

Circulating inflammatory indicators are powerful CVD predictors with important roles in atherosclerosis development [59]. CRP is released by the liver and is the most reliable and substantial predictor of CVD risk [60]. Leukocytes and endothelial cells expressing soluble VCAM-1 and ICAM-1 can stimulate the activation and adhesion at the inflammatory site, promoting atherosclerotic processes at the endothelial surface [61]. Plasma soluble ICAM-1 and sVCAM-1 concentrations have been linked to CVD incidence and can be used to predict the risk of cardiovascular events [62]. Selectins, such as sE-selectin and sP-selectin, can participate in ischemia-reperfusion damage, arterial and venous thrombosis, atherosclerosis, and other CVDs by facilitating signal transduction and leukocyte adhesion at the vascular wall [63]. The meta-analysis by Lorzadeh et al. [64] included 6 RCTs and indicated that hesperidin significantly reduces VCAM-1 but not CRP, E-selectin, and ICAM-1. By contrast, we found significant changes in CRP and ICAM-1 after hesperidin consumption.

It should be noted that bioavailability is a critical factor in evaluating the therapeutic effect of oral medicine. Solubility and permeability through biological membranes play a significant role in influencing the bioavailability [65]. Hesperidin has a chiral carbon at position 2, resulting in 2 diastereoisomers, 2R and 2S, with the 2S-diastereoisomer being the prevalent form in nature [66]. Hesperidin presents a low solubility that may affect its absorption and, therefore, its bioavailability. Several studies have shown differences in transport, metabolism, biological effects, and kinetics between the 2 hesperidin diastereoisomers in plasma and urine [[67], [68], [69]]. Thus, the bioavailability of hesperidin is an important issue that must be considered when examining its efficacy. Future research should focus on the relationships between the bioavailability of hesperidin and delivery systems. In addition, there is a need to standardize a hesperidin intervention protocol, including the consistency of dosage, duration of administration, and pharmaceutical dosage forms.

This study is superior to previous systematic reviews and meta-analyses [24,25] for the following reasons: first, we used stringent inclusion and exclusion criteria and considered only RCTs to guarantee the inclusion of high-quality data during synthesis. Therefore, to our knowledge, this meta-analysis was the most recent, critical, in-depth, comparative investigation, which typically redefined and strengthened earlier study conclusions. Second, we conducted several subgroup analyses based on mean age, study design, baseline BMI, intervention duration, and hesperidin dose to investigate the effects of hesperidin intervention across various factors. Third, we performed the analyses of sensitivity and publication bias to obtain more objective decisions and did not find substantial publication bias. Finally, we used restricted maximum likelihood–based dose–response analysis to find an optimal duration and dosage for hesperidin intervention. In addition, we conducted the criteria of GRADE to evaluate the clinical evidence’s overall body and the recommendation’s strength for each outcome, different from previous studies.

Although this updated meta-analysis has promising results, some limitations are also present. First, the bias of publication was not significant using both Begg rank correlation tests and Egger linear regression. However, we found significant heterogeneity among trials for TG (I2 = 80%), QUICKI (I2 = 99%), CRP (I2 = 56%), E-selectin (I2 = 59%), VCAM-1 (I2 = 87%), and ICAM-1 (I2 = 62%) outcomes. The potential causes of the heterogeneity are likely attributable to variations in study quality, the dosage of hesperidin consumed, dietary habits, and individual characteristics such as age, sex, and baseline BMI. Sensitivity, meta-regression, and a priori subgroup analyses did not completely solve the sources of heterogeneity. Second, the studies included in this meta-analysis, specifically on some CVD markers such as HC, E-selectin, VCAM-1, and ICAM-1, were not enough, providing inconclusive results. Therefore, these findings must be interpreted cautiously, and more large-scale, high-quality clinical studies are required to get conclusive results. Third, the habits of consumption is believed to affect the lipid profile, blood pressure, and other CVD risk factors significantly in clinics. Because the intervention periods of the included studies were very short (3–12 wk), we could not assess the long-term effect of hesperidin therapy on CVDRFs. Finally, despite the included studies being designed as RCTs, most were classified as unclear based on our risk-of-bias assessment, implying that more research might significantly impact the confidence in the estimated effects.

In conclusion, this meta-analysis of RCTs indicated that citrus flavanone hesperidin supplementation could significantly improve TC, LDL cholesterol, FBG, QUICKI, CRP, VCAM-1, and ICAM-1. However, no beneficial effect were found in HDL cholesterol, TG, SBP, DBP, insulin, HOMA-IR, BW, BMI, WC, HC, or E-selectin. The changes in CVD biomarkers were affected by the trial design, supplement dosage, mean age, baseline BMI, and intervention duration. Our findings might help health care practitioners and the general public better comprehend the data on the CVD preventive benefits of hesperidin. Nevertheless, further long-term clinical studies with more homogenous doses and bigger populations are recommended to get a more exact and comprehensive conclusion on the impact of hesperidin on CVDRFs.

Author contributions

The authors’ responsibilities were as follows – HH: conceived and designed the study, performed acquisition of data, analysis and interpretation of data, drafted the manuscript, discussed the idea of the meta-analysis, submitted the paper; DL, BH: completed the database searches and selected, reviewed the articles, and extracted the data; GZ, YC: reviewed and extracted the data and performed the data analyses; and all authors: read and approved the final version of the manuscript.

Conflict of interest

The authors declare that they have no competing interest.

Funding

This work was supported by the Traditional Medicine Research Program of Guangdong Province (Grant No. 20211410 ) and Medical Scientific Research Foundation of Guangdong Province (Grant No. A2021356 ).

Data availability

The data sets used and/or analyzed during this study are available from the corresponding author on reasonable request.

Appendix A Supplementary data

The following is the Supplementary data to this article:Multimedia component1

Multimedia component1

Appendix A Supplementary data to this article can be found online at https://doi.org/10.1016/j.cdnut.2023.102055.
==== Refs
References

1 Roth G.A. Huffman M.D. Moran A.E. Feigin V. Mensah G.A. Naghavi M. Global and regional patterns in cardiovascular mortality from 1990 to 2013 Circulation 132 2015 1667 1678 26503749
2 Widmer R.J. Flammer A.J. Lerman L.O. Lerman A. The Mediterranean diet, its components, and cardiovascular disease Am. J. Med. 128 2015 229 238 25447615
3 Piepoli M.F. Hoes A.W. Agewall S. Albus C. Brotons C. Catapano A.L. European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur. Heart J. 37 2016 2016 2315 2381 27222591
4 Yusuf S. Hawken S. Ounpuu S. Dans T. Avezum A. Lanas F. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 2004 937 952 15364185
5 Hong K.N. Fuster V. Rosenson R.S. Rosendorff C. Bhatt D.L. How low to go with glucose, cholesterol, and blood pressure in primary prevention of CVD J. Am. Coll. Cardiol. 70 2017 2171 2185 29050566
6 Hetherington I. Totary-Jain H. Anti-atherosclerotic therapies: milestones, challenges, and emerging innovations Mol. Ther. 30 2022 3106 3117 36065464
7 Tucker W.J. Fegers-Wustrow I. Halle M. Haykowsky M.J. Chung E.H. Kovacic J.C. Exercise for primary and secondary prevention of cardiovascular disease: JACC Focus Seminar ¼ J. Am. Coll. Cardiol. 80 2022 1091 1106 36075680
8 Huang H. Liao D. Dong Y. Pu R. Effect of quercetin supplementation on plasma lipid profiles, blood pressure, and glucose levels: a systematic review and meta-analysis Nutr. Rev. 78 2020 615 626 31940027
9 Huang H. Zhou G. Pu R. Cu Y. Liao D. Clinical evidence of dietary supplementation with sesame on cardiovascular risk factors: an updated meta-analysis of randomized controlled trials Crit. Rev. Food. Sci. Nutr. 62 2022 5592 5602 33612009
10 Vogiatzoglou A. Mulligan A.A. Lentjes M.A. Luben R.N. Spencer J.P. Schroeter H. Flavonoid intake in European adults (18 to 64 years) PLoS One 10 2015 e0128132
11 Wu G.A. Terol J. Ibanez V. López-García A. Pérez-Román E. Borredá C. Genomics of the origin and evolution of citrus Nature 554 2018 311 316 29414943
12 Tomas-Barberan F.A. Clifford M.N. Flavanones, chalcones and dihydrochalcones—nature, occurrence and dietary burden J. Sci. Food Agric. 80 2000 1073 1080
13 Leuzzi U. Caristi C. Panzera V. Licandro G. Flavonoids in pigmented orange juice and second-pressure extracts J. Agric. Food Chem. 48 2000 5501 5506 11087509
14 Li C. Schluesener H. Health-promoting effects of the citrus flavanone hesperidin Crit. Rev. Food Sci. Nutr. 57 2017 613 631 25675136
15 Pandey P. Khan F. A mechanistic review of the anticancer potential of hesperidin, a natural flavonoid from citrus fruits Nutr. Res. 92 2021 21 31 34273640
16 Pyrzynska K. Hesperidin: a review on extraction methods, stability and biological activities Nutrients 14 2022 2387 35745117
17 Mas-Capdevila A. Teichenne J. Domenech-Coca C. Caimari A. Del Bas J.M.D. Escoté X. Effect of hesperidin on cardiovascular disease risk factors: the role of intestinal microbiota on hesperidin bioavailability Nutrients 12 2020 1488 32443766
18 Iskender H. Dokumacioglu E. Sen T.M. Ince I. Kanbay Y. Saral S. The effect of hesperidin and quercetin on oxidative stress, NF-κB and SIRT1 levels in a STZ-induced experimental diabetes model Biomed. Pharmacother. 90 2017 500 508 28395272
19 Mahmoud A.M. Ashour M.B. Abdel-Moneim A. Ahmed O.M. Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fat fed/streptozotocin-induced type 2 diabetic rats J. Diabetes Complications. 26 2012 483 490 22809898
20 Salden B.N. Troost F.J. de Groot E. Stevens Y.R. Garcés-Rimón M. Possemiers S. Randomized clinical trial on the efficacy of hesperidin 2S on validated cardiovascular biomarkers in healthy overweight individuals Am. J. Clin. Nutr. 104 2016 1523 1533 27797708
21 Homayouni F. Haidari F. Hedayati M. Zakerkish M. Ahmadi K. Blood pressure lowering and anti-inflammatory effects of hesperidin in type 2 diabetes; a randomized double-blind controlled clinical trial Phytother. Res. 32 2018 1073 1079 29468764
22 Ohara T. Muroyama K. Yamamoto Y. Murosaki S. Oral intake of a combination of glucosyl hesperidin and caffeine elicits an anti-obesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial Nutr. J. 15 2016 6 26786000
23 Yari Z. Movahedian M. Imani H. Alavian S.M. Hedayati M. Hekmatdoost A. The effect of hesperidin supplementation on metabolic profiles in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial Eur. J. Nutr. 59 2020 2569 2577 31844967
24 Mohammadi M. Ramezani-Jolfaie N. Lorzadeh E. Khoshbakht Y. Salehi-Abargouei A. Hesperidin, a major flavonoid in orange juice, might not affect lipid profile and blood pressure: a systematic review and meta-analysis of randomized controlled clinical trials Phytother. Res. 33 2019 534 545 30632207
25 Pla-Pagà L. Companys J. Calderón-Pérez L. Llauradó E. Solà R. Valls R.M. Effects of hesperidin consumption on cardiovascular risk biomarkers: a systematic review of animal studies and human randomized clinical trials Nutr. Rev. 77 2019 845 864 31271436
26 Kean R.J. Lamport D.J. Dodd G.F. Freeman J.E. Williams C.M. Ellis J.A. Chronic consumption of flavanone-rich orange juice is associated with cognitive benefits: an 8-wk, randomized, double-blind, placebo-controlled trial in healthy older adults Am. J. Clin. Nutr. 101 2015 506 514 25733635
27 Constans J. Bennetau-Pelissero C. Martin J.F. Rock E. Mazur A. Bedel A. Marked antioxidant effect of orange juice intake and its phytomicronutrients in a preliminary randomized cross-over trial on mild hypercholesterolemic men Clin. Nutr. 34 2015 1093 1100 25865966
28 Rangel-Huerta O.D. Aguilera C.M. Martin M.V. Soto M.J. Rico M.C. Vallejo F. Normal or high polyphenol concentration in orange juice affects antioxidant activity, blood pressure, and body weight in obese or overweight adults J. Nutr. 145 2015 1808 1816 26136593
29 Schär M.Y. Curtis P.J. Hazim S. Ostertag L.M. Kay C.D. Potter J.F. Orange juice-derived flavanone and phenolic metabolites do not acutely affect cardiovascular risk biomarkers: a randomized, placebo-controlled, crossover trial in men at moderate risk of cardiovascular disease Am. J. Clin. Nutr. 101 2015 931 938 25788001
30 Buscemi S. Rosafio G. Arcoleo G. Mattina A. Canino B. Montana M. Effects of red orange juice intake on endothelial function and inflammatory markers in adult subjects with increased cardiovascular risk Am. J. Clin. Nutr. 95 2012 1089 1095 22492368
31 Aptekmann N.P. Cesar T.B. Orange juice improved lipid profile and blood lactate of overweight middle-aged women subjected to aerobic training Maturitas 67 2010 343 347 20729016
32 Cesar T.B. Aptekmann N.P. Araujo M.P. Vinagre C.C. Maranhão R.C. Orange juice decreases low-density lipoprotein cholesterol in hypercholesterolemic subjects and improves lipid transfer to high-density lipoprotein in normal and hypercholesterolemic subjects Nutr. Res. 30 2010 689 694 21056284
33 Page M.J. McKenzie J.E. Bossuyt P.M. Boutron I. Hoffmann T.C. Mulrow C.D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ 372 2021 n71 33782057
34 Higgins J.P. Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [Internet], updated March 2011. Available from: http://handbook.cochrane.org/
35 Higgins J.P. Thompson S.G. Deeks J.J. Altman D.G. Measuring inconsistency in meta-analyses BMJ 327 2003 557 560 12958120
36 Begg C.B. Mazumdar M. Operating characteristics of a rank correlation test for publication bias Biometrics 50 1994 1088 1101 7786990
37 Egger M. Davey Smith G. Schneider M. Minder C. Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634 9310563
38 Morton S.C. Adams J.L. Suttorp M.J. Shekelle P.G. Meta-regression approaches: what, why, when, and how? 2004 Agency for Healthcare Research and Quality Rockville, MD
39 Guyatt G.H. Oxman A.D. Vist G.E. Kunz R. Falck-Ytter Y. Alonso-Coello P. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BMJ 336 2008 924 926 18436948
40 Cheraghpour M. Imani H. Ommi S. Alavian S.M. Karimi-Shahrbabak E. Hedayati M. Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled, double-blind clinical trial Phytother. Res. 33 2019 2118 2125 31264313
41 Demonty I. Lin Y. Zebregs Y.E.M.P. Vermeer M.A. van der Knaap H.C.M. Jäkel M. The citrus flavonoids hesperidin and naringin do not affect serum cholesterol in moderately hypercholesterolemic men and women J Nutr 140 2010 1615 1620 20660284
42 Haidari F. Heybar H. Jalali M.T. Engali K.A. Helli B. Shirbeigi E. Hesperidin supplementation modulates inflammatory responses following myocardial infarction J. Am. Coll. Nutr. 34 2015 205 211 25757593
43 Homayouni F. Haidari F. Hedayati M. Zakerkish M. Ahmadi K. Hesperidin supplementation alleviates oxidative DNA damage and lipid peroxidation in type 2 diabetes: a randomized double-blind placebo-controlled clinical trial Phytother. Res. 31 2017 1539 1545 28805022
44 Morand C. Dubray C. Milenkovic D. Lioger D. Martin J.F. Scalbert A. Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers Am. J. Clin. Nutr. 93 2011 73 80 21068346
45 Rizza S. Muniyappa R. Iantorno M. Kim J.A. Chen H. Pullikotil P. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome J. Clin. Endocrinol. Metab. 96 2011 E782 E792 21346065
46 Yari Z. Cheraghpour M. Alavian S.M. Hedayati M. Eini-Zinab H. Hekmatdoost A. The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial Eur J Clin Nutr 75 2021 99 111 32647367
47 Yari Z. Cheraghpour M. Hekmatdoost A. Flaxseed and/or hesperidin supplementation in metabolic syndrome: an open-labeled randomized controlled trial Eur. J. Nutr. 60 2021 287 298 32296931
48 Jokić S. Šafranko S. Jakovljević M. Cikoš A.-M. Kajić N. Kolarević F. Sustainable green procedure for extraction of hesperidin from selected Croatian mandarin peels Processes 7 2019 469
49 Isomaa B. Almgren P. Tuomi T. Forsén B. Lahti K. Nissén M. Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care 24 2001 683 689 11315831
50 Lloyd-Jones D. Adams R.J. Brown T.M. Carnethon M. Dai S. De Simone G. Heart disease and stroke statistics—2010 update: a report from the American Heart Association Circulation 121 2010 e46 e215 20019324
51 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 19 2001 2486 2497 11368702
52 Jung U.J. Lee M.K. Park Y.B. Kang M.A. Choi M.-S. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice Int. J. Biochem. Cell Biol. 38 2006 1134 1145 16427799
53 Lee Y.S. Huh J.Y. Nam S.H. Moon S.K. Lee S.B. Enzymatic bioconversion of citrus hesperidin by Aspergillus sojae naringinase: enhanced solubility of hesperetin-7-O-glucoside with in vitro inhibition of human intestinal maltase, HMG-CoA reductase, and growth of Helicobacter pylori Food Chem 135 2012 2253 2259 22980799
54 Gómez-Zorita S. Lasa A. Abendaño N. Fernández-Quintela A. Mosqueda-Solís A. Garcia-Sobreviela M.P. Phenolic compounds apigenin, hesperidin and kaempferol reduce in vitro lipid accumulation in human adipocytes J. Transl. Med. 15 2017 237 29162103
55 Shams-Rad S. Mohammadi M. Ramezani-Jolfaie N. Zarei S. Mohsenpour M. Salehi-Abargouei A. Hesperidin supplementation has no effect on blood glucose control: A systematic review and meta-analysis of randomized controlled clinical trials Br J Clin Pharmacol 86 2020 13 22 31489695
56 Akiyama S. Katsumata S. Suzuki K. Nakaya Y. Ishimi Y. Uehara M. Hypoglycemic and hypolipidemic effects of hesperidin and cyclodextrin-clathrated hesperetin in Goto-Kakizaki rats with type 2 diabetes Biosci. Biotechnol. Biochem. 73 2009 2779 2782 19966469
57 Sundaram R. Nandhakumar E. Haseena Banu H. Hesperidin, a citrus flavonoid ameliorates hyperglycemia by regulating key enzymes of carbohydrate metabolism in streptozotocin-induced diabetic rats Toxicol. Mech. Methods. 29 2019 644 653 31345080
58 Dhanya R. Jayamurthy P. In vitro evaluation of antidiabetic potential of hesperidin and its aglycone hesperetin under oxidative stress in skeletal muscle cell line Cell Biochem. Funct. 38 2020 419 427 31926116
59 Libby P. Inflammation and cardiovascular disease mechanisms Am. J. Clin. Nutr. 83 2006 456S 460S 16470012
60 Curb J.D. Abbott R.D. Rodriguez B.L. Sakkinen P. Popper J.S. Yano K. C-reactive protein and the future risk of thromboembolic stroke in healthy men Circulation 107 2003 2016 2020 12681999
61 Habas K. Shang L. Alterations in intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) in human endothelial cells Tissue Cell 54 2018 139 143 30309503
62 Mulvihill N.T. Foley J.B. Crean P. Walsh M. Prediction of cardiovascular risk using soluble cell adhesion molecules Eur. Heart J. 23 2002 1569 1574 12323155
63 McEver R.P. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall Cardiovasc. Res. 107 2015 331 339 25994174
64 Lorzadeh E. Ramezani-Jolfaie N. Mohammadi M. Khoshbakht Y. Salehi-Abargouei A. The effect of hesperidin supplementation on inflammatory markers in human adults: a systematic review and meta-analysis of randomized controlled clinical trials Chem. Biol. Interact. 307 2019 8 15 30991044
65 Hua S. Advances in oral drug delivery for regional targeting in the gastrointestinal tract—influence of physiological, pathophysiological and pharmaceutical factors Front. Pharmacol. 11 2020 524 32425781
66 Lévèques A. Actis-Goretta L. Rein M.J. Williamson G. Dionisi F. Giuffrida F. UPLC-MS/MS quantification of total hesperetin and hesperetin enantiomers in biological matrices J. Pharm. Biomed. Anal. 57 2012 1 6 21920690
67 Brand W. Shao J. Hoek-van den Hil E.F. van Elk K.N. Spenkelink B. de Haan L.H.J. Stereoselective conjugation, transport and bioactivity of s- and R-hesperetin enantiomers in vitro J. Agric. Food Chem. 58 2010 6119 6125 20441166
68 Yáñez J.A. Remsberg C.M. Miranda N.D. Vega-Villa K.R. Andrews P.K. Davies N.M. Pharmacokinetics of selected chiral flavonoids: hesperetin, naringenin and eriodictyol in rats and their content in fruit juices Biopharm. Drug Dispos. 29 2008 63 82 18058792
69 Yáñez J.A. Teng X.W. Roupe K.A. Davis N.M. Stereospecific high-performance liquid chromatographic analysis of hesperetin in biological matrices J. Pharm. Biomed. Anal. 37 2005 591 595 15740921
